Ligand efficiency indices for effective drug discovery

Bibliography

• CAMPBELL SF: Science, art and drug discovery: a personal perspective. Clin. Sci. (Lond) (2000) 99(4):255-260.
   PubMed Web of Science ®Google Scholar
• CONGREVE M, MURRAY CW, BLUNDELL TL: Structural biology and drug discovery. Drug Discov. Today (2005) 10(13):895-907.
   PubMed Web of Science ®Google Scholar
• TINTELNOT-BLOMLEY M, LEWIS RA: A critical appraisal of structure-based drug design. IDrugs (2006) 9(2):114-118.
   PubMed Web of Science ®Google Scholar
• WALSH MA, DEMENTIEVA I, EVANS G, SANISHVILI R, JOACHIMIAK A: Taking MAD to the extreme: ultrafast protein structure determination. Acta Crystallogr. D Biol. Crystallogr. (1999) 55(Pt. 6):1168-1173.
   PubMed Web of Science ®Google Scholar
• DAUTER Z: Current state and prospects of macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. (2006) 62(Pt. 1):1-11.
   PubMed Web of Science ®Google Scholar
• VEDADI M, NIESEN FH, ALLALI-HASSANI A et al.: Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA (2006) 103(43):15835-15840.
   PubMed Web of Science ®Google Scholar
• ADAMS MD, CELNIKER SE, HOLT RA et al.: The genome sequence of Drosophila melanogaster. Science (2000) 287(5461):2185-2195.
   PubMed Web of Science ®Google Scholar
• JIANG J, SWEET RM: Protein Data Bank depositions from synchrotron sources. J. Synchrotron Radiat. (2004) 11(Pt. 4):319-327.
   PubMed Web of Science ®Google Scholar
• BERMAN HM, WESTBROOK J, FENG Z et al.: The Protein Data Bank. Nucleic Acids Res. (2000) 28(1):235-242.
   PubMed Web of Science ®Google Scholar
• KUNTZ ID, CHEN K, SHARP KA, KOLLMAN PA: The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA (1999) 96(18):9997-10002.
   PubMed Web of Science ®Google Scholar
• HOPKINS AL, GROOM CR, ALEX A: Ligand efficiency: a useful metric for lead selection. Drug Discov. Today (2004) 9(10):430-431.
   PubMed Web of Science ®Google Scholar
• ABAD-ZAPATERO C, METZ JM: Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today (2005) 10(7):464-469.
   PubMed Web of Science ®Google Scholar
• PALM K, STENBERG P, LUTHMAN K, ARTURSSON P: Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. (1997) 14(5):568-571.
   PubMed Web of Science ®Google Scholar
• CONGREVE M, CARR R, MURRAY C, JHOTI H: A ‘rule of three’ for fragment-based lead discovery? Drug Discov. Today (2003) 8:876-877.
   PubMed Web of Science ®Google Scholar
• ABAD-ZAPATERO C, STAMPER GF, STOLL VS: Synergistic use of protein-crystallography and solution-phase NMR spectroscopy in structure-based drug design: strategies and tactics. In: Fragment-based Approaches in Drug Discovery. Jahnke W, Erlanson DA (Eds), Wiley-VCH Verlag GmbH & Co., Weinheim, Germany (2006):249-266.
   Google Scholar
• SCHNECKE V, BROSTROM J: Computational chemistry-driven decision making in lead generation. Drug Discov. Today (2006) 11:43-50.
   PubMed Web of Science ®Google Scholar
• WUNBERG T, HENDRIX M, HILLISCH A et al.: Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today (2006) 11(3-4):175-180.
   PubMed Web of Science ®Google Scholar
• KESERU GM, MAKARA MG: Hit discovery and hit-to-lead approaches. Drug Discovery Today (2006) 11(15/16):741-748.
   PubMed Web of Science ®Google Scholar
• LEACH AR, HANN MM: Fragment screening: an Introduction. Mol. Biosyst. (2006) 2:429-446.
   Web of Science ®Google Scholar
• REES DC, CONGREVE M, MURRAY CW, CARR R: Fragment-based lead discovery. Nat. Rev. Drug Discov. (2004) 3:660-672.
   PubMed Web of Science ®Google Scholar
• CARR RA, CONGREVE M, MURRAY CW, REES DC: Fragment-based lead discovery: leads by design. Drug Discov. Today (2005) 10(14):987-992.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ, SHEPPARD G, NETTESHEIM DG et al.: Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. (1997) 119:5818-5827.
   Web of Science ®Google Scholar
• JAHNKE W, ERLANSON DA: Fragment-based Approaches in Drug Discovery. Jahnke W, Erlanson DA (Eds), Wiley-VCH Verlach GmbH, Weinheim, Germany (2006).
   Google Scholar
• LEACH AR, SHOICHET BK, PEISHOFF CE: Prediction of protein–ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. (2006) 49(20):5851-5855.
   PubMed Web of Science ®Google Scholar
• HAJDUK PJ: Fragment-based drug design: how big is too big? J. Med. Chem. (2006) 49(24):6972-6976.
   PubMed Web of Science ®Google Scholar
• OPREA TI, DAVIS AM, TEAGUE JJ, LEESON PD: Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. (2001) 41:1308-1315.
   PubMedGoogle Scholar
• PROUDFOOT JR: Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. (2002) 12(12):1647-1650.
   PubMed Web of Science ®Google Scholar
• ROEHRIG S, STRAUB A, POHLMANN J et al.: Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J. Med. Chem. (2005) 48(19):5900-5908.
   PubMed Web of Science ®Google Scholar
• MESTRES J, VEENEMAN GH: Identification of ‘latent hits’ in compound screening collections. J. Med. Chem. (2003) 46(16):3441-3444.
   PubMed Web of Science ®Google Scholar
• BEMIS GW, MURCKO MA: The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. (1996) 39(15):2887-2893.
   PubMed Web of Science ®Google Scholar
• VIETH M, SUTHERLAND JJ: Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. (2006) 49(12):3451-3453.
   PubMed Web of Science ®Google Scholar
• MORPHY R: The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. (2006) 49(10):2969-2978.
   PubMed Web of Science ®Google Scholar
• BLANEY J, NIENABER V, BURLEY SK: Fragment-based lead discovery and optimization using X-ray crystallography, computational chemistry, and high-throughput organic synthesis. In: Fragment-based Approaches in Drug Discovery, Jahnke W, Erlanson DA (Eds), Wiley-VCH, Weinheim, Germany (2006):215-248.
   Google Scholar
• HAJDUK PJ, HUTH JR, FESIK SW: Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. (2005) 48(7):2518-2525.
   PubMed Web of Science ®Google Scholar
• SADOWSKI J, KUBINYI H: A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. (1998) 41(18):3325-3329.
   PubMed Web of Science ®Google Scholar
• FRIMURER TM, BYWATER R, NAERUM L, LAURITSEN LN, BRUNAK S: Improving the odds in discriminating ‘drug-like’ from ‘non drug-like’ compounds. J. Chem. Inf. Comput. Sci. (2000) 40(6):1315-1324.
   PubMedGoogle Scholar
• WARREN GL, ANDREWS CW, CAPELLI AM et al.: A critical assessment of docking programs and scoring functions. J. Med. Chem. (2006) 49(20):5912-5931.
   PubMed Web of Science ®Google Scholar
• PEARLMAN DA: Evaluating the molecular mechanics poisson-Boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. J. Med. Chem. (2005) 48(24):7796-7807.
   PubMed Web of Science ®Google Scholar
• AKRITOPOULOU-ZANZE I, DARCZACK D, SARRIS K et al.: Scaffold oriented synthesis. Part 1: design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors. Biorg. Med. Chem. Lett. (2006) 16:96-99.
   PubMed Web of Science ®Google Scholar
• SHERMAN W, BEARD HS, FARID R: Use of an induced fit receptor structure in virtual screening. Chem. Biol. Drug Des. (2006) 67(1):83-84.
   PubMed Web of Science ®Google Scholar
• SHERMAN W, DAY T, JACOBSON MP, FRIESNER RA, FARID R: Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. (2006) 49(2):534-553.
   PubMed Web of Science ®Google Scholar
• IRWIN JJ, RAUSHEL FM, SHOICHET BK: Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry (2005) 44:12316-12328.
   PubMed Web of Science ®Google Scholar
• PEI Z, LIU G, LUBBEN TH, SZCZEPANKIEWICZ BG: Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity. Curr. Pharm. Des. (2004) 10(28):3481-3504.
   PubMed Web of Science ®Google Scholar
• SZCZEPANKIEWICZ BG, LIU G, HAJDUK PJ et al.: Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. (2003) 125(14):4087-4096.
   PubMed Web of Science ®Google Scholar
• XIN Z, OOST TK, ABAD-ZAPATERO C et al.: Potent, selective inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett. (2003) 13(11):1887-1890.
   PubMed Web of Science ®Google Scholar
• LIU G, SZCZEPANKIEWICZ BG, PEI Z et al.: Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. (2003) 46(11):2093-2103.
   PubMed Web of Science ®Google Scholar
• LIU G, XIN Z, LIANG H et al.: Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J. Med. Chem. (2003) 46(16):3437-3440.
   PubMed Web of Science ®Google Scholar
• PEI Z, LI X, LIU G et al.: Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett. (2003) 13(19):3129-3132.
   PubMed Web of Science ®Google Scholar
• LIU G, XIN Z, PEI Z et al.: Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J. Med. Chem. (2003) 46(20):4232-4235.
   PubMed Web of Science ®Google Scholar
• XIN Z, LIU G, ABAD-ZAPATERO C et al.: Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett. (2003) 13(22):3947-3950.
   PubMed Web of Science ®Google Scholar
• ZHAO H, LIU G, XIN Z et al.: Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(22):5543-5546.
   PubMed Web of Science ®Google Scholar
• IVERSEN LF, ANDERSEN HS, BRANNER S et al.: Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J. Biol. Chem. (2000) 275(14):10300-10307.
   PubMed Web of Science ®Google Scholar
• ANDERSEN HS, IVERSEN LF, JEPPESEN CB et al.: 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. (2000) 275(10):7101-7108.
   PubMed Web of Science ®Google Scholar
• SZCZEPANKIEWICZ BG, LIU G, HAJDUK PJ et al.: Discovery of a potent, selective protein tyrosine phosphatase 1B Inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. (2003) 125:4087-4096.
   PubMed Web of Science ®Google Scholar
• MARTIN YC: A bioavailability score. J. Med. Chem. (2005) 48(9):3164-3170.
   PubMed Web of Science ®Google Scholar
• WISHART DS, KNOX C, GUO AC et al.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. (2006) 34(Database issue):D668-D672.
   PubMed Web of Science ®Google Scholar
• VON GELDERN TW, LAI CH, GUM RJ et al.: Benzoxazole benzesulfonamides are novel allosteric inhibitors of fructose-1,6-bisphosphatase with a distinct binding mode. Biorg. Med. Chem. Lett. (2006) 16:1811-18115.
   PubMed Web of Science ®Google Scholar
• LAI CH, GUM RJ, DALY M et al.: Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase. Biorg. Med. Chem. Lett. (2006) 16:1807-1810.
   PubMed Web of Science ®Google Scholar
• STEWART KD, SHIRODA M, JAMES CA: Drug Guru: a computer software program for drug design using medicinal chemistry rules. Bioorg. Med. Chem. (2006) 14(20):7011-7022.
   PubMed Web of Science ®Google Scholar
• WENLOCK MC, AUSTIN RP, BARTON P, DAVIS AM, LEESON PD: A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. (2003) 46(7):1250-1256.
   PubMed Web of Science ®Google Scholar
• VIETH M, SIEGEL MG, HIGGS RE et al.: Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. (2004) 47(1):224-232.
   PubMed Web of Science ®Google Scholar
• LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods (2000) 44(1):235-249.
   PubMed Web of Science ®Google Scholar
• VEBER DF, JOHNSON SR, CHENG HY et al.: Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. (2002) 45(12):2615-2623.
   PubMed Web of Science ®Google Scholar